Intraoperative Immunotherapy to Improve Survival Outcomes Post

Surge Therapeutics is pioneering a transformative approach to cancer treatment through its innovative intraoperative immunotherapy. The company has developed a biodegradable hydrogel that can be injected at the site of surgical tumor resection. This hydrogel is designed to extend the localized release of cancer immunotherapy, allowing for a concentrated dose to be delivered precisely where it is needed. By focusing the therapeutic effect at the surgical site, Surge aims to reprogram the body’s immune response from being immunosuppressive—often triggered by surgery—to an immunostimulatory one. This localized approach not only targets residual cancer cells but also seeks to generate systemic immunity, potentially preventing post-surgical recurrence and metastasis.

The need for such an innovative solution is underscored by the high rates of cancer relapse following surgery, with over 40% of patients experiencing a recurrence within five years. Surge's technology addresses this critical gap in cancer care by concentrating immunotherapy at the tumor site, which can help overcome local immune tolerance and reduce systemic toxicity. The company’s research, grounded in findings from Harvard Medical School, positions its hydrogel as a promising investigational drug that could redefine the standard of care for cancer patients undergoing surgery, ultimately aiming to improve survival outcomes and reduce cancer-related deaths.

United States

SURGE seeks to dramatically improve cancer patient survival by disrupting how, when, and where cancer immunotherapy is deployed -- focusing 100% of the effective dose at the right place and at the right time. 

Surgery is the standard of care for most patients with solid tumors, and we are working tirelessly to ensure that nobody grieves the loss of a loved one to preventable post-surgical cancer recurrence.

Surge Therapeutics

Company Details